Meeting
2021 ASCO Annual Meeting
Lisinopril or carvedilol in prevention of trastuzumab-induced cardiotoxicity in patients with HER2-positive early stage breast cancer: Longitudinal changes of left ventricular ejection fraction below normal levels (LVEF <50%).
Authors
Pamela N. Munster
University of California San Francisco, San Francisco, CA
Pamela N. Munster , Roy Tamura , Jeffrey Krischer , Worta J. McCaskill-Stevens , Maya Guglin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT01009918
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 509)
DOI
10.1200/JCO.2021.39.15_suppl.509
Abstract #
509
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.
First Author: Beverly Moy
Poster
2018 ASCO Annual Meeting
Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early‑stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.
First Author: Bent Ejlertsen
Poster
2017 ASCO Annual Meeting
Changes in p16INK4a (p16) expression, a biomarker of aging, in peripheral blood T-cells (PBTC) in patients receiving anthracycline (A) vs non-anthracycline (NoA) chemotherapy (CRx) for early-stage breast cancer (EBC).
First Author: Shlomit Strulov Shachar